Keyphrases
18F-FDG PET-CT
24%
5-fluorouracil (5-FU)
41%
5-year Survival
15%
Adenocarcinoma
19%
Advanced Esophageal Cancer
32%
Advanced Gastric Cancer
16%
Bevacizumab
16%
Biochemical Failure
16%
Brain Metastases
16%
Cancer Patients
14%
Capecitabine
17%
Cetuximab
16%
Chemoradiation
19%
Chemoradiotherapy
18%
Cisplatin
37%
Clinical Entities
16%
Colorectal Cancer
85%
Concurrent Chemoradiotherapy
26%
Diarrhea
13%
Disease-free Survival
20%
Docetaxel
12%
Early Prediction
16%
Esophageal Adenocarcinoma
17%
Esophageal Cancer
40%
Gastric Cancer
31%
Histological Response
13%
Israel
32%
Leucovorin
24%
Locally Advanced
17%
Locally Advanced Rectal Cancer
21%
MicroRNA
12%
Neoadjuvant
14%
Neoadjuvant Chemoradiotherapy (nCRT)
56%
Neoadjuvant Therapy
39%
Overall Survival
27%
Partial Response
18%
Pathological Complete Response
31%
Pathological Response
17%
Phase II Study
16%
Positron Emission Tomography-computed Tomography (PET-CT)
32%
Preoperative Chemoradiation
20%
Prognostic Factors
13%
Radiation Therapy
14%
Radiotherapy
42%
Rectal Tumor
14%
Three-dimensional Conformal Radiotherapy
16%
Treatment Options
21%
Tumor
47%
Tumor Regression Grade
21%
Young Patients
17%
Medicine and Dentistry
Abdominal Cancer
24%
Adenocarcinoma
31%
Biochemical Recurrence
16%
Biopsy Technique
8%
Brain Metastasis
16%
Breast Cancer
17%
Cancer Treatment
11%
Capecitabine
9%
Cetuximab
8%
Chemoradiotherapy
100%
Colon Carcinoma
24%
Colorectal Carcinoma
36%
Computer Assisted Tomography
11%
Conformal Radiotherapy
16%
Disease Free Survival
17%
Diseases
18%
Esophageal Adenocarcinoma
17%
Esophageal Cancer
42%
Family History
8%
Fluorine-18
16%
Fluorodeoxyglucose F 18
16%
Fluorouracil
11%
Folinic Acid
16%
Gastroesophageal Junction
12%
Hazard Ratio
10%
Lymph Node
9%
Malignant Neoplasm
23%
Metastatic Carcinoma
9%
microRNA
16%
Neoadjuvant Chemotherapy
12%
Neoadjuvant Therapy
37%
Neoplasm
80%
Overall Survival
26%
Pelvic Radiotherapy
10%
Positron Emission Tomography
9%
Positron Emission Tomography-Computed Tomography
40%
Primary Tumor
11%
Prognostic Factor
19%
Prostate Cancer
9%
Radiation Therapy
49%
Rectum Cancer
77%
Rectum Tumor
11%
Recurrent Disease
16%
Retrospective Study
27%
Signet Ring Cell
9%
Sphincter
12%
Squamous Cell Carcinoma
10%
Survival Rate
8%
Systematic Review
8%
Tumor Regression
18%
Pharmacology, Toxicology and Pharmaceutical Science
Abdominal Cancer
61%
Adenocarcinoma
22%
Bevacizumab
16%
Biochemical Recurrence
16%
Bone Metastasis
8%
Brain Metastasis
16%
Breast Cancer
9%
Capecitabine
17%
Cetuximab
16%
Chemoradiation Therapy
98%
Chemotherapy
33%
Cisplatin
39%
Colon Carcinoma
16%
Colorectal Carcinoma
18%
Diarrhea
7%
Disease Free Survival
12%
Diseases
25%
Docetaxel
16%
Esophageal Squamous Cell Carcinoma
8%
Esophagus Cancer
29%
Fluorine 18
8%
Fluorodeoxyglucose F 18
8%
Fluorouracil
38%
Folinic Acid
16%
Gemcitabine
8%
Liver Cell Carcinoma
8%
Long Term Survival
8%
Malignant Neoplasm
17%
microRNA
16%
microRNA 29a
8%
Minimal Residual Disease
8%
Neoplasm
55%
Overall Survival
26%
Pancreas Cancer
8%
Polyethylene Terephthalate
32%
Primary Tumor
11%
Progression Free Survival
8%
Prospective Cohort Study
8%
Prostate Cancer
10%
Rectum Cancer
48%
Recurrent Disease
17%
Retrospective Study
13%
Stomach Carcinoma
8%
Survival Rate
12%
Tolerability
10%
Tumor Regression
6%